Impact Factor
3.04
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.11
293 total citations
h5-index
20
h5 depth signal
Cited share
66.7%
98 of 147
Total citations
293
Citation footprint
Metric signal
1.99
External metric anchor
Self-citation
2.0%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
278
Italy
93
China
80
France
73
Australia
55
Citing Fields of Research
Oncology
517
Dermatology
402
Immunology
338
Breast Cancer
77
Ophthalmology
73
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,249
Articles tracked across the journal lifetime
Indexed publication set
147
98 cited publications
Last 12 months
76
6.3 publications/month
Open access share
14.5%
11 OA publications in the last year
Leading citing country
United States
278 citing publications
Leading citing field
Oncology
517 citing publications
Latest tracked publication
6 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Apr./May 1991-
v1n1,Apr./May 1991-
Active Coverage
Research Focus & Classification
Indexed Subjects
Dermatology
Oncology
Immunology
Broad Categories
Neoplasms
Dermatology
Immunology
MeSH Descriptors
Melanoma
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/cmr.0000000000001143
Open DOI
Comprehensive analysis and external validation of a glycolysis-related gene signature as a prognostic index for skin cutaneous melanoma
Skin cutaneous melanoma (SKCM) is the third most common cause of cancer-related deaths globally. Today, precise biomarkers to predict melanoma prognosis are quite limited. Aerobic glycolysis serves as the primary metabolic pathway for ma...
02
DOI 10.1097/cmr.0000000000001142
Open DOI
Comprehensive role of fluorine-18-labeled fluorodeoxyglucose PET/computed tomography across the disease course of primary malignant melanoma of the esophagus
This study aimed to evaluate the clinical value of fluorine-18-labeled fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) in managing primary malignant melanoma of the esophagus (PMME). Seventy patients with pathologically confi...
03
DOI 10.1097/cmr.0000000000001139
Open DOI
Dissociation between systemic inflammatory markers and the tumor microenvironment in predicting sentinel lymph node metastasis in cutaneous melanoma
Systemic inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), are established prognostic biomarkers in melanoma, particularly in advanced disease. However, their utility in predicti...
04
DOI 10.1097/cmr.0000000000001144
Open DOI
Association between perioperative antidepressant use and postoperative outcomes after cutaneous melanoma resection
Cutaneous melanoma is the fifth most common cancer in the USA and the most fatal form of skin cancer. Antidepressants (ADPs) are among the most commonly prescribed medications in this population and may influence postoperative recovery t...
05
DOI 10.1097/cmr.0000000000001141
Open DOI
Transcriptomic immune subtyping and connectivity mapping nominate DNA methyltransferase inhibitors for immunedepleted melanoma
Immune-cold melanomas respond poorly to immune checkpoint blockade (ICB). We assessed whether RNA-seq-based immune subtyping and connectivity mapping could nominate repurposable compounds to shift immune-depleted melanoma toward an immun...
06
DOI 10.1097/cmr.0000000000001132
Open DOI
DPM2 promotes melanoma progression and serves as a prognostic factor
Recently, dolichol phosphate mannose synthase (DPMS) has emerged as a promising new target for treatment in various cancers. Nonetheless, DPM2, a crucial element of the DPMS family, remains unexplored in melanoma research. This study aim...
07
DOI 10.1097/cmr.0000000000001135
Open DOI
Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literature
Combined B-Raf proto-oncogene, serine/threonine kinase/MAPK kinase (BRAF/MEK) inhibition, along with immune checkpoint inhibition, has significantly improved the outcomes of patients with advanced melanoma harboring BRAF V600 mutations. ...
08
DOI 10.1097/cmr.0000000000001130
Open DOI
NF1 alterations as potential biomarker in acral melanoma: looking beyond low tumor mutational burden
Was not provided for this article.
09
DOI 10.1097/cmr.0000000000001126
Open DOI
Scalp melanoma presents with greater Breslow thickness and higher metastatic burden: analysis of 105 Korean cutaneous head and neck melanoma patients
Cutaneous head and neck melanoma (CHNM) accounts for a disproportionate share of melanoma-related mortality, yet the prognostic value of its precise anatomical site remains uncertain. We retrospectively reviewed 105 patients with CHNM di...
10
DOI 10.1097/cmr.0000000000001124
Open DOI
A modern review of uveal melanoma: molecular insights, clinical management, and emerging therapies
Uveal melanoma is the most frequent primary intraocular malignancy in adults and is characterized by an aggressive clinical course, high propensity for hepatic metastasis, and poor survival after metastatic progression. Improvements in o...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 1, no. 1 (APRIL-MAY 1991)19920709 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper